Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripretinib vs Sunitinib in GIST with KIT exon 11+17/18 mutations
NCT05734105Phase 3Active, not recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of ripretinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Deciphera Pharmaceuticals. Primary endpoint: Progression-Free Survival up to 48 months. Started Dec 2023; status: active, not recruiting.
02
Drugs
ripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05734105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05734105.